The GLP-1 class is the most-studied and fastest-growing area of metabolic medicine. These peptides mimic incretin hormones to enhance insulin secretion, suppress glucagon, slow gastric emptying and reduce appetite — driving substantial weight loss and glycemic improvement. The newer dual and triple agonists (tirzepatide, retatrutide) hit multiple receptors at once for progressively larger effects.
Below is every PeptideXR profile, evidence review and head-to-head comparison covering this class, each grounded in the primary literature.
Profiles
- CagriSema: Mechanism, Benefits & Research Evidence
- Cagrilintide: Mechanism, Benefits & Research Evidence
- Mazdutide: Mechanism, Benefits & Research Evidence
- Retatrutide: Mechanism, Benefits & Research Evidence
- Semaglutide: Mechanism, Benefits & Research Evidence
- Tirzepatide: Mechanism, Benefits & Research Evidence
Comparisons
- Cagrilintide vs Semaglutide: A Comparative Analysis of GLP-1 Receptor Agonists
- Retatrutide vs Cagrilintide: Exploring Their Potential in Metabolic Disorders
- Semaglutide vs Retatrutide: A Comparative Analysis of Two Emerging Treatments for Metabolic Disorders
- Semaglutide vs Tirzepatide: A Comparative Analysis of GLP-1 Receptor Agonists
- Tirzepatide vs Retatrutide: A Comparative Analysis of Two Emerging Peptide Therapies
Questions & Evidence
- How does retatrutide's glucagon agonism avoid the hepatic glucose output problem that killed earlier glucagon-containing therapies, and what does the answer tell us about long-term liver risk?
- If retatrutide's weight loss curve is steeper than tirzepatide's mostly because of glucagon-driven energy expenditure, does that mean the true comparator isn't another GLP-1 — it's DNP, and we should be asking the same safety questions?